Prognosis and clinicopathologic features in patients with gastric stump cancer after curative surgery

C.Y. Kung MD,*† W.L. Fang MD PhD,*† R.F. Wang MD PhD,† C.A. Liu MD,§|| A.F.Y. Li MD PhD,‡
C.W. Wu MD,*† Y.M. Shyr MD,*,† S.C. Chou MD,*,† and K.H. Huang MD PhD*§a

ABSTRACT

Background Gastric stump (“remnant”) cancer is the development of a malignancy related to previous gastric surgery. Prognosis in gastric stump cancer, compared with that in primary gastric cancer, is still controversial.

Methods From January 1988 to December 2012 at a single medical centre in Taiwan, 105 patients with gastric stump cancer, including 85 with previous peptic ulcer disease and 20 with previous gastric cancer, were analyzed for clinicopathologic characteristics and overall survival (os).

Results The 5-year os rates for patients with gastric stump cancer and with primary gastric cancer were 51.2% and 54.5% respectively (p = 0.035). Analysis of clinicopathologic characteristics indicated that, compared with patients having primary gastric cancer, those with gastric stump cancer had more lymph node metastasis (p < 0.001) and had been diagnosed at a more advanced stage (p = 0.047). Multivariate analysis with os as an endpoint showed that age [p = 0.015; hazard ratio (HR): 2.300; 95% confidence interval (CI): 1.173 to 4.509], tumour size (p = 0.037; HR: 1.700; 95% CI: 1.031 to 2.801), stromal reaction (p = 0.021; HR: 1.802; 95% CI: 1.094 to 2.969), and pathologic N category (p = 0.001; HR: 1.449; 95% CI: 1.161 to 1.807) were independent predictors in gastric stump cancer. The os rates for patients with gastric stump cancer who previously had gastric cancer or peptic ulcer disease were 72.9% and 50.0% respectively (p = 0.019). The Borrmann classification was more superficial (p = 0.005), lymph node metastases were fewer (p = 0.004), and staging was less advanced (p = 0.025) in patients with gastric stump cancer who previously had gastric cancer than in their counterparts who previously had peptic ulcer disease.

Conclusions Survival is poorer in patients with gastric stump cancer who previously had peptic ulcer disease than in those who previously had primary gastric cancer. Patients with gastric stump cancer who previously had gastric cancer and could receive curative gastrectomy tended to have a better prognosis because of a more superficial Borrmann classification. Regular follow-up in patients who have undergone gastric surgery is recommended for the early detection of gastric stump cancer.

Key Words Gastric remnant cancer, gastric stump cancer, peptic ulcers, gastrectomy

Curr Oncol. 2020 June:27(3)e259–e264 www.current-oncology.com

INTRODUCTION

Gastric cancer is a common malignancy in the upper gastrointestinal tract. It is currently the 3rd leading cause of cancer-related deaths worldwide. The treatment for gastric cancer is surgical resection, with curative intent for patients without distant metastasis. Extended regional D2 lymph node dissection is a standard procedure in gastric cancer surgery. The incidence of gastric cancer has been declining in recent decades, but the incidence of gastric stump cancer is increasing because of prior peptic ulcer surgery and a long latency period.

Gastric stump (“remnant”) cancer is defined as a malignancy occurring in the gastric stump at least 5 years after the previous operation. This type of cancer is thought to be associated with chronic inflammation and is often diagnosed at an advanced stage. Regular follow-up of patients after gastric surgery is recommended to detect early signs of gastric stump cancer.

These authors contributed equally to the present work.
GASTRIC STUMP CANCER AFTER CURATIVE SURGERY, Kung et al.

Gastrectomy. The development of the malignancy is associated with prior gastric surgery, including procedures for peptic ulcer disease or previous gastric cancer. Because of reconstruction of the gastrointestinal tract after gastrectomy, including Billroth type I and Billroth type II procedures, the gastric stump is affected by reflux of bile acids, resulting in gastrointestinal and further intestinal metaplasia and dysplasia of the gastric mucosa. Those alterations eventually develop and transform into gastric carcinoma. Moreover, gastric stump cancer is typically found to be a more advanced gastric cancer associated with a relatively lower curative resection rate. However, the clinicopathologic characteristics and prognosis for gastric stump cancer, compared with those for primary gastric cancer, are still controversial. In the present study, we investigated the clinicopathologic characteristics and prognosis in gastric stump cancer and evaluated differences between patients who previously had benign peptic ulcer disease and those who had gastric cancer.

METHODS

In this retrospective study, the charts of 126 patients with gastric stump cancer who underwent gastrectomy from January 1998 to December 2012 at the Department of Surgery in Taipei Veterans General Hospital, Taiwan, were reviewed. Of those patients, 105 received curative resection, and 21 received palliative surgery. Of the 105 patients treated curatively, 85 had previously undergone gastrectomy because of peptic ulcer disease, and 20, because of previous gastric cancer (Figure 1). During the study period, 2622 patients with primary gastric cancer who received curative surgery were enrolled for comparison with the patients who had gastric stump cancer.

Before their operation, all patients underwent upper gastrointestinal endoscopy, chest radiography, and either or both of abdominal sonography and abdominal computed tomography for clinical tumour staging. Patients who could not undergo curative surgery—those receiving palliative resection and those with unresectable tumours, peritoneal carcinomatosis, or distant metastases (bone, lung, liver)—were excluded from the study. Patients whose pathology report showed other than adenocarcinoma were also excluded.

Radical total gastrectomy was performed for proximal-third lesions, and radical subtotal gastrectomy was performed for distal- or middle-third lesions. At least D1+ lymph node dissection was performed for early gastric cancer, and a D2 lymph node dissection was performed for advanced gastric cancer. Basic demographic and clinical data for the patients were collected, including age, sex, tumour location, tumour size, gross appearance, histology analyses, lymph node metastasis status, and pathologic stage.

Gross features of the specimens were based on tumour size, tumour location, and Borrmann classification. The Borrmann classifications were superficial type, Borrmann type I (polypoid tumour), Borrmann type II (ulcerated tumour with sharply demarcated margin), Borrmann type III (ulcerated tumour without a demarcated margin and infiltrating to surrounding gastric wall), and Borrmann type IV (diffuse infiltrating tumour). Borrmann types I and II are well-defined tumours (localized type); Borrmann types III and IV are ill-defined tumours (infiltrating type). The microscopic features—histology, pathology, and cell differentiation—were analyzed by cell grading for tumour differentiation, stromal reaction type (medullary, intermediate, or scirrhous), Lauren histologic classification (intestinal or diffuse), Ming histologic classification (expanding or infiltrating), and lymphovascular invasion patterns. The staging system used was the TNM system.

After surgery, patients were followed at the outpatient clinic every 3 months for at least the first 5 years after gastrectomy, and every 6 months thereafter (patients not experiencing disease relapse or recurrence for more than 5 years). Before 2008, adjuvant chemotherapy or radiotherapy, or both, were not routinely performed after curative surgery, but were provided to patients with gastric cancer at the time of tumour recurrence. After 2008, the adjuvant oral fluoropyrimidine S-1 was prescribed in our hospital, if the patient found it financially affordable, for stage II or III gastric cancer after curative resection.

Recurrence was defined as first evidence of tumour relapse in imaging, in cytology analysis of ascites from an abdominal tap, in endoscopy findings, or in bone scans. The relapse pattern was recorded in detail. Follow-up data were prospectively collected and regularly updated. Survival in patients with gastric cancer was followed for more than 10 years. Overall survival was defined as the period from the date of surgery to the date of death or last follow-up. Disease-free survival was defined as the period from the date of surgery for gastric cancer during which the patient survived without recurrence.

The study was approved by the Institutional Review Board of Taipei Veterans General Hospital (IRB-TPEVGH no. 2018-06-005BC).

All statistical analyses were carried out using the IBM SPSS Statistics software application (version 19.0: IBM, Armonk, NY, U.S.A.). Clinicopathologic differences were compared using the chi-square test. Survival was evaluated using Kaplan–Meier analysis with log-rank test. Prognostic factors such as age, sex, tumour size, Borrmann classification, cell grade, Lauren histology, stromal reaction, lymphovascular invasion, and T and N stage were evaluated in a Cox regression model with OS as an endpoint. A p value less than 0.05 was considered statistically significant.

RESULTS

The R0 resection rate in gastric stump cancer was 83.3%; in primary gastric cancer, it was 87.8%. The mean age of
patients with gastric stump cancer (69.4 ± 10.0 years) was greater than that of patients with primary gastric cancer (66.6 ± 12.6 years, \(p = 0.036\)). The male:female ratio was also greater in patients with gastric stump cancer than in those with primary gastric cancer, \(p = 0.004\). Analysis of clinicopathologic characteristics indicates that, compared with their counterparts having primary gastric cancer, patients with gastric stump cancer had more lymph node metastasis (\(p < 0.001\)) and were diagnosed at a more advanced stage (\(p = 0.047\), Table 1).

The 5-year OS rates for patients with gastric stump cancer and with primary gastric cancer were 51.2% and 54.5% respectively (\(p = 0.035\)). The 5-year disease-free survival rates of patients with gastric stump cancer and with primary gastric cancer were 46.2% and 54.1% respectively (\(p = 0.043\), Figure 2).

Multivariate analysis with OS as an endpoint showed that age [\(p = 0.015\]; hazard ratio (HR): 2.300; 95% confidence interval (CI): 1.173 to 4.509], tumour size (\(p = 0.037\); HR: 1.700; 95% CI: 1.031 to 2.801), stromal reaction (\(p = 0.021\); HR: 1.802; 95% CI: 1.094 to 2.969), and pathologic N stage (\(p = 0.001\); HR: 1.449; 95% CI: 1.161 to 1.807) were independent predictors in gastric stump cancer (Table 1).

The median latency period for the 105 patients with gastric stump cancer was 25.7 years. It was significantly longer for patients who previously had peptic ulcer disease than for those who previously had gastric cancer (27.3 years vs. 11.8 years, \(p < 0.001\)). With respect to the anastomosis procedure in patients with gastric stump cancer, Billroth I anastomoses had been created in 5 patients with previous peptic ulcer disease and in 6 with previous gastric cancer; Billroth II anastomoses had been created in 80 and 14 patients respectively (\(p = 0.002\)). We found that 16 of the 94 patients with Billroth II anastomoses had mesentery lymph node metastases, for a positive rate of 17.0%. In comparing the clinicopathologic features of the groups with a prior gastric cancer history, the Borrmann classification was more superficial (\(p = 0.025\)), lymph node metastases were fewer (\(p = 0.004\)), and staging was less advanced (\(p = 0.025\)) in patients with a prior gastric cancer history (Table iii). The 5-year OS was poorer in patients with gastric stump cancer after prior peptic ulcer disease than in those after primary gastric cancer (\(p = 0.019\), Figure 3).

### DISCUSSION

Although the incidence of gastric cancer has declined in recent decades, the prevalence of gastric stump cancer has not yet declined because of the long latency after prior gastric surgery. Our results show that, compared with patients having primary gastric cancer, those with gastric stump cancer have more lymph node metastasis and are diagnosed at a more advanced stage. The prognosis in gastric stump cancer is also poorer than that in primary gastric cancer. Because of the long latency after prior gastric surgery, gastric stump cancer will remain an important medical issue in the coming decades.

Compared with patients whose gastric stump cancer was related to prior peptic ulcer disease, those whose gastric stump cancer was related to a prior gastric cancer history

| Variable | Gastric stump cancer | Primary gastric cancer | \(p\) Value \(^a\) |
|----------|----------------------|------------------------|------------------|
| Patients (n) | 105 | 2622 | |
| Mean age (years) | 68.9±9.6 | 66.6±12.6 | 0.036 |
| Sex [n (%)] | | | |
| Men | 91 (86.7) | 1952 (74.4) | |
| Women | 14 (13.3) | 672 (25.6) | 0.004 |
| Tumour size group [n (%)] | | | |
| <4 cm | 50 (47.6) | 1135 (43.3) | |
| 4–8 cm | 42 (40.0) | 1131 (43.1) | |
| >8 cm | 13 (12.4) | 356 (13.6) | 0.679 |
| Differentiation [n (%)] | | | |
| Poorly differentiated | 48 (45.7) | 1375 (52.4) | |
| Moderately differentiated | 54 (51.4) | 1177 (44.9) | |
| Well differentiated | 3 (2.9) | 70 (2.7) | 0.398 |
| Gross appearance [n (%)] | | | |
| Superficial | 41 (39.0) | 979 (37.3) | |
| Borrmann type I–II | 22 (21.0) | 518 (19.8) | |
| Borrmann type III–IV | 42 (40.0) | 1125 (42.9) | 0.839 |
| Stromal reaction type [n (%)] | | | |
| Medullary | 31 (29.5) | 698 (26.6) | |
| Intermediate | 55 (52.4) | 1286 (49.1) | |
| Scirrhous | 19 (18.1) | 638 (24.3) | 0.337 |
| Lauren histology [n (%)] | | | |
| Intestinal type | 66 (62.9) | 1507 (57.5) | |
| Diffuse type | 39 (37.1) | 1115 (42.5) | 0.274 |
| Ming histology [n (%)] | | | |
| Expanding | 33 (31.4) | 806 (30.7) | |
| Infiltrating | 72 (68.6) | 1816 (69.3) | 0.881 |
| Lymphovascular invasion [n (%)] | | | |
| No | 39 (37.1) | 1117 (42.6) | |
| Yes | 66 (62.9) | 1505 (57.4) | 0.267 |
| Pathologic T stage [n (%)] | | | |
| T1 | 40 (38.1) | 922 (35.2) | |
| T2 | 28 (26.7) | 684 (26.1) | |
| T3 | 19 (18.1) | 626 (23.9) | 0.566 |
| T4 | 18 (17.1) | 390 (14.9) | |
| Pathologic N stage [n (%)] | | | |
| N0 | 34 (32.4) | 1262 (48.1) | |
| N1 | 22 (21.0) | 465 (17.7) | |
| N2 | 27 (25.7) | 327 (12.5) | |
| N3 | 22 (20.9) | 568 (21.7) | <0.001 |
| TNM stageb [n (%)] | | | |
| I | 39 (37.1) | 1250 (47.7) | |
| II | 22 (21.0) | 556 (21.2) | |
| III | 44 (41.9) | 816 (31.1) | 0.047 |
| 5-Year OS rate (%) | 51.2 | 54.5 | 0.035 |
| 5-Year DFS rate (%) | 46.2 | 54.1 | 0.043 |

\(^a\) Significant values are shown in boldface type.
\(^b\) According to the American Joint Committee on Cancer staging manual, 8th edition.

OS = overall survival; DFS = disease-free survival.
had a relatively better prognosis. Ahn et al.\textsuperscript{11} reported that the difference in os between patients who previously had a benign disease and those who had a previous cancer was nonsignificant. However, Hu et al.\textsuperscript{12} reported that prognosis was better for patients with gastric stump cancer after prior benign disease than for their counterparts after a prior gastric cancer. In contrast, our study showed that prognosis was relatively better for patients with gastric stump cancer after a prior history of gastric cancer than after a prior history of benign peptic ulcer disease. Because patients with gastric remnant cancer after a prior history of gastric cancer were regularly followed at our outpatient clinic and regularly received upper gastrointestinal endoscopy, abdominal sonography, or abdominal computed tomography, recurrent tumours at the gastric remnant could be detected early. Patients with a prior history of benign peptic ulcer disease have a longer latency period to gastric stump cancer after gastrectomy for ulcer disease. Because of that long latency period, those patients did not receive regular follow-up at our clinic. Hence, their stump cancer was not detected early in its development. They were diagnosed when symptoms such as obstruction or tumour bleeding developed. Prognosis is therefore relatively poorer for patients with peptic ulcer–related gastric stump cancer than for those whose stump recurrence was related to gastric cancer. It is very important that regular upper gastrointestinal endoscopy be performed for patients who have undergone gastric surgery for peptic ulcer disease.

Some researchers have compared the prognosis in gastric stump cancer with that in gastric cancer in the high body or cardia regions\textsuperscript{13-16}. In our study, the 5-year os and disease-free survival rates for primary cardia or high-body gastric cancer compared with gastric stump cancer were, respectively, 55.6% and 51.2% (\(p = 0.057\)) and 52.3% and 46.2% (\(p = 0.069\)). Although we observed a trend in our series toward a poorer prognosis for patients with gastric stump cancer, the differences were not statistically significant. To the best of our knowledge, the anatomic structure of gastric stump cancer is, because of previous gastric surgery, quite different from that of primary gastric cancer in the cardia or high-body regions. In addition, most gastric stump cancers develop around the anastomotic site of the gastroduodenostomy in Billroth \(i\) reconstructions and of the gastrojejunostomy in Billroth \(ii\) reconstructions\textsuperscript{17}. The development of gastric stump cancer might be associated with reflux of bile and pancreas secretions, resulting in inflammation and degeneration of the gastric mucosa. Because of persistent gastritis and atrophic gastritis, the gastric mucosa develops intestinal metaplasia and dysplasia, which eventually transforms into gastric adenocarcinoma. The environment of the gastric remnant is quite different from that of the natural anatomic structure of gastric cancer in the high-body and cardia regions.

In the literature, the resectability of gastric stump cancer ranges from 71% to 94%. The R0 resection rate in gastric stump cancer ranges from 77% to 85\%\textsuperscript{3}. The rates of resectability and R0 resection in gastric stump cancer are

\begin{table}
\centering
\caption{Multivariate analysis with overall survival as an endpoint, \(105\) patients with gastric stump cancer}
\begin{tabular}{|l|c|c|c|}
\hline
Variable & Analysis & \(p\) Value\textsuperscript{a} & HR & 95\% CI \\
\hline
Age & \textbf{0.015} & 2.300 & 1.173 to 4.509 \\
Sex & 0.309 & 1.612 & 0.642 to 4.045 \\
Tumour size & \textbf{0.037} & 1.700 & 1.031 to 2.801 \\
Borrmann classification & 0.547 & 0.883 & 0.590 to 1.323 \\
Differentiation & 0.867 & 0.569 & 0.193 to 1.680 \\
Lauren histology & 0.308 & 2.300 & 1.173 to 4.509 \\
Stromal reaction & \textbf{0.021} & 1.802 & 1.094 to 2.969 \\
Lymphovascular invasion & 0.901 & 1.056 & 0.448 to 2.489 \\
Pathologic T stage\textsuperscript{b} & 0.451 & 1.157 & 0.792 to 1.697 \\
Pathologic N stage\textsuperscript{b} & \textbf{0.001} & 1.449 & 1.161 to 1.807 \\
\hline
\end{tabular}
\textsuperscript{a} Significant values are shown in boldface type.
\textsuperscript{b} According to the American Joint Committee on Cancer staging manual, 8th edition.
\textsuperscript{HR} = hazard ratio; CI = confidence interval.
\end{table}


### TABLE III
Clinical profile of patients with gastric stump cancer and prior ulcer disease or prior gastric cancer

| Variable                                      | Prior ulcer disease | Prior gastric cancer | \( p \) Value<sup>a</sup> |
|-----------------------------------------------|---------------------|----------------------|---------------------------|
| Patients (n)                                  | 85                  | 20                   |                           |
| Mean age (years)                              | 69.4±10.0           | 66.5±8.9             | 0.239                     |
| Incubation period (years)                     | 27.3                | 11.8                 | <0.001                    |
| Reconstruction method [n (%)]                 |                     |                      |                           |
| B-I anastomosis                               | 5 (5.9)             | 6 (30)               |                           |
| B-II anastomosis                              | 80 (94.1)           | 14 (70)              | 0.002                     |
| Sex [n (%)]                                   |                     |                      |                           |
| Men                                           | 75 (88.2)           | 16 (80)              |                           |
| Women                                         | 10 (11.8)           | 4 (20)               | 0.330                     |
| Tumour size group [n (%)]                     |                     |                      |                           |
| <4 cm                                         | 37 (43.5)           | 13 (65)              |                           |
| 4–8 cm                                        | 36 (42.4)           | 6 (30)               |                           |
| >8 cm                                         | 12 (14.1)           | 1 (5)                | 0.195                     |
| Differentiation [n (%)]                       |                     |                      |                           |
| Poorly differentiated                         | 39 (46.0)           | 9 (45)               |                           |
| Moderately differentiated                     | 45 (52.9)           | 9 (45)               |                           |
| Well differentiated                           | 1 (1.1)             | 2 (10)               | 0.100                     |
| Gross appearance [n (%)]                      |                     |                      |                           |
| Superficial type                              | 27 (31.8)           | 14 (70)              |                           |
| Borrmann type I–II                            | 21 (24.7)           | 1 (5)                |                           |
| Borrmann type III–IV                          | 37 (43.5)           | 5 (25)               | 0.005                     |
| Stromal reaction type [n (%)]                 |                     |                      |                           |
| Medullary                                     | 22 (25.9)           | 9 (45)               |                           |
| Intermediate                                  | 47 (55.3)           | 8 (40)               |                           |
| Scirrhous                                     | 16 (18.8)           | 3 (15)               | 0.240                     |
| Lauren histology [n (%)]                      |                     |                      |                           |
| Intestinal type                               | 53 (62.4)           | 13 (65)              |                           |
| Diffuse type                                  | 32 (37.6)           | 7 (35)               | 0.826                     |
| Ming histology [n (%)]                        |                     |                      |                           |
| Expanding                                     | 25 (29.4)           | 8 (40)               |                           |
| Infiltrating                                  | 60 (70.6)           | 12 (60)              | 0.359                     |
| Lymphovascular invasion [n (%)]               |                     |                      |                           |
| No                                            | 28 (32.9)           | 11 (55)              |                           |
| Yes                                           | 57 (67.1)           | 9 (45)               | 0.066                     |
| Pathologic T stage [n (%)]                    |                     |                      |                           |
| T1                                            | 28 (32.9)           | 12 (60)              |                           |
| T2                                            | 16 (18.8)           | 2 (10)               |                           |
| T3                                            | 23 (27.1)           | 5 (25)               |                           |
| T4                                            | 18 (21.2)           | 1 (5)                | 0.102                     |
| Pathologic N stage [n (%)]                    |                     |                      |                           |
| N0                                            | 23 (27.1)           | 11 (55)              |                           |
| N1                                            | 15 (17.6)           | 7 (35)               |                           |
| N2                                            | 26 (30.6)           | 1 (5)                |                           |
| N3                                            | 21 (24.7)           | 1 (5)                | 0.004                     |

**TABLE III** Continued

| Variable                                      | Prior ulcer disease | Prior gastric cancer | \( p \) Value<sup>a</sup> |
|-----------------------------------------------|---------------------|----------------------|---------------------------|
| TNM stage [n (%)]                             |                     |                      |                           |
| I                                             | 28 (33.0)           | 11 (55)              | 0.025                     |
| II                                            | 16 (18.8)           | 6 (30)               |                           |
| III                                           | 41 (48.2)           | 3 (15)               |                           |
| 5-Year OS rate (%)                            | 50                   | 72.9                 | 0.019                     |
| 5-Year DFS rate (%)                           | 46.7                 | 45.7                 | 0.953                     |

<sup>a</sup> Significant values are shown in boldface type.
<sup>b</sup> According to the American Joint Committee on Cancer staging manual, 8th edition.

OS = overall survival; DFS = disease-free survival.

lower than those in primary proximal-third gastric cancer. In our series, the R0 resection rate in gastric stump cancer was 83.3%; for primary gastric cancer, it was 87.8%. In multivariate analysis, larger tumour size and greater stromal reaction were independent predictors for gastric stump cancer. Surgeons are therefore challenged in attempting curative resection for very advanced gastric stump cancer.

Lymph node metastasis plays an important role in gastric cancer. It is also an important prognostic factor in gastric stump cancer. The main lymphatic drainage pathway is usually along the gastric cardia region, the left gastric artery, and the splenic artery. Radical lymph node dissection is therefore still necessary, as recommended by the Japanese Gastric Cancer Association. In addition, a previous publication reported that the drainage pathway for lymph node metastasis is along the anastomotic site of the jejunal. In our cohort, 16 of 94 patients (17.0%) had mesentry lymph node metastases after Billroth II anastomotic procedures. Resection of the jejunal mesentery near the anastomotic site is therefore still recommended in patients who receive a Billroth II anastomosis.

Our study reports on a 25-year experience in a single centre, based on a retrospective investigation. We collected data from patients with gastric cancer who underwent curative resection and who had complete pathology examinations and follow-up survival data. Selection bias might have be a factor in this retrospective cohort study. We focused on the clinicopathologic characteristics and clinical outcomes of patients with gastric stump cancer.

### CONCLUSIONS

Survival was poorer in patients with gastric stump cancer than in patients with primary gastric cancer. Because of a more superficial Borrmann classification, prognosis tended to be better in patients with gastric stump cancer who previously had gastric cancer treated with curative gastrectomy. Regular follow-up in patients who have previously undergone gastric surgery is recommended for the early detection of gastric stump cancer. Further studies are necessary to evaluate environmental alterations in the gastric remnant and tumour behaviour in gastric stump cancer.
ACKNOWLEDGMENTS

We thank Miss L.J. Dai (Department of Surgery, Taipei Veterans General Hospital) for assistance with statistics. This study was supported in part by a grant from the Ministry of Science and Technology [MOST no. 107-2314-B-075-005-MY2] and grants from Taipei Veterans General Hospital (nos. V107C-043 and V108C-070).

CONFLICT OF INTEREST DISCLOSURES

We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.

AUTHOR AFFILIATIONS

*Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, †School of Medicine, National Yang-Ming University, ‡Department of Emergency Medicine, Taipei City Hospital, Ren-Ai Branch, §Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, ||Department of Radiology, Taipei Veterans General Hospital, and #Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. *Int J Cancer* 2015;1:136:E359–86.
2. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomized controlled trial. *Lancet Oncol* 2006;7:309–15.
3. Sinning C, Schaefer N, Standop J, Hirner MW, M Wolff. Gastric stump carcinoma—epidemiology and current concepts in pathogenesis and treatment. *Eur J Surg Oncol* 2007;33:133–9.
4. Lagerrgen J, Lindam A, Mason RM. Gastric stump cancer after distal gastrectomy for benign gastric ulcer in a population-based study. *Int J Cancer* 2012;131:E1048–52.
5. Mekmirk J, Gonen M, Ammori JB, Strong VE, Brennan MF, Coit DG. Treatment and outcome of patients with gastric remnant cancer after resection for peptic ulcer disease. *Ann Surg Oncol* 2011;18:670–6.
6. Thorban S, Bottcher K, Efter M, Roder JD, Busch R, Siewert JR. Prognostic factors in gastric stump cancer. *Ann Surg* 2000;231:188–94.
7. Komatsu S, Ichikawa D, Okamoto K, et al. Progression of remnant gastric cancer is associated with duration of follow-up following distal gastrectomy. *World J Gastroenterol* 2012;18:2832–6.
8. Huang H, Wang W, Chen Z, et al. Prognostic factors and survival in patients with gastric stump cancer. *World J Gastroenterol* 2015;21:1865–71.
9. Ming SC. Gastric carcinoma: a pathological classification. *Cancer* 1977;39:2475–85.
10. American Joint Committee on Cancer. *AJCC Cancer Staging Manual*. 8th ed. Chicago, IL: Springer; 2017.
11. Ahn HE, Kim JW, Yoo MW, et al. Clinicopathological features and surgical outcomes of patients with remnant gastric cancer after a distal gastrectomy. *Ann Surg Oncol* 2008;15:1632–9.
12. Hu X, Tian DY, Cao L, Yi Y. Progression and prognosis of gastric stump cancer. *J Surg Oncol* 2009;100:472–6.
13. Schaefer N, Sinning C, Standop J, Overhaus M, Hirner A, Wolff M. Treatment and prognosis of gastric stump carcinoma in comparison with primary proximal gastric cancer. *Am J Surg* 2007;194:63–7.
14. An YJ, Choi MG, Noh JH, Sohn TS, Kim S. The outcome of patients with remnant primary gastric cancer compared with those having upper one-third gastric cancer. *Am J Surg* 2007;194:143–7.
15. Wang Y, Huang CM, Wang JB, et al. Survival and surgical outcomes of cardiac cancer of the remnant stomach in comparison with primary cardiac cancer. *World J Surg Oncol* 2014;12:21.
16. Komatsu S, Ichikawa D, Okamoto K, et al. Difference of the lymphatic distribution and the surgical outcomes between remnant gastric cancer and primary proximal gastric cancer. *J Gastrointest Surg* 2012;16:503–8.
17. Tanigawa N, Nomura E, Lee SW, et al. Current state of gastric stump carcinoma in Japan: based on the results of a nationwide survey. *World J Surg* 2010;34:1540–7.
18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 3rd English edition. *Gastric Cancer* 2011:14:101–12.
19. Han SL, Hua YW, Wang CH, Ji SQ, Zhuang J. Metastatic pattern of lymph node and surgery for gastric stump cancer. *J Surg Oncol* 2013;82:241–6.